Prolia (Denosumab) Patient Assistance for Low-Income Patients

Why Prolia Costs $1,500 Per Injection

Prolia is a fully human monoclonal antibody that inhibits RANK ligand, the protein signal that activates osteoclasts and drives bone resorption. Its biologic manufacturing process accounts for much of the cost. A single 60 mg prefilled syringe carries a wholesale acquisition cost (WAC) of roughly $1 to 500 in 2026, and patients receive one injection every six months.

In the FREEDOM trial (N=7,868), denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo [1]. The 10-year FREEDOM Extension (N=4,550) confirmed sustained fracture risk reduction with continued treatment, with vertebral fracture incidence remaining below 2% annually through year 10 [2]. These outcomes explain why the Endocrine Society's 2019 clinical practice guideline lists denosumab as a first-line option for postmenopausal osteoporosis, particularly in patients who cannot tolerate oral bisphosphonates.

The clinical necessity creates a problem. Stopping denosumab abruptly can trigger rebound vertebral fractures within 7 to 12 months of the last dose [3]. Patients who start Prolia because of cost assistance need a reliable, long-term plan to avoid gaps in therapy.

Amgen Safety Net Foundation: Free Prolia for Qualifying Patients

The most direct route to free Prolia is Amgen's Safety Net Foundation, a 501(c)(3) charitable program that provides Amgen medications at no cost to eligible patients. The foundation covers uninsured and underinsured patients whose household income falls at or below 300% of the federal poverty level (FPL). For a single individual in 2026, that threshold is approximately $47,520 per year.

Enrollment requires a signed application, proof of income (tax return or pay stubs), and a prescription from the treating physician. Approval typically takes 2 to 4 weeks. Once approved, the foundation ships Prolia directly to the prescribing physician's office. Patients pay nothing for the medication itself, though some offices charge a separate administration fee for the injection.

Dr. Andrea Singer, Director of Bone Density Services at MedStar Georgetown University Hospital, has stated: "Patient assistance programs like Amgen's Safety Net Foundation are often the only viable path for uninsured patients with severe osteoporosis. The key is applying before the first dose is needed so there is no treatment gap" [4].

Reapplication is required annually. Patients should submit renewal paperwork at least 30 days before their next scheduled injection to prevent a lapse in coverage. The foundation does not cover patients enrolled in any government insurance program, including Medicare Part D or Medicaid.

Amgen FIRST STEP Copay Program for Commercially Insured Patients

Patients with commercial (private) insurance who face high copays or coinsurance can apply for the Amgen FIRST STEP program. This copay assistance card can reduce the out-of-pocket cost to as little as $5 per injection, with a maximum annual benefit that varies by year (typically $10,000 to $15,000 per calendar year).

Eligibility requirements are straightforward. Patients must have commercial insurance that covers Prolia, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, VA), and must be a U.S. resident. There is no income threshold for the copay card. The card is presented at the point of service, and the discount is applied automatically.

One common mistake: patients assume the FIRST STEP card works like a coupon at a pharmacy. It does not. Because Prolia is a physician-administered injectable, the card is processed through the medical benefit (not the pharmacy benefit) at the provider's billing office. Patients should confirm with their provider's billing team that they accept manufacturer copay cards for buy-and-bill medications before their appointment.

Medicare Part B Coverage of Prolia

Medicare Part B covers Prolia because it is administered by injection in a healthcare provider's office, placing it under the medical benefit rather than the Part D prescription drug benefit. According to CMS billing guidelines, the HCPCS code for denosumab is J0897, and Medicare reimburses providers based on the Average Sales Price (ASP) plus 6%.

After meeting the annual Part B deductible ($257 in 2026), Medicare pays 80% of the approved amount. The remaining 20% coinsurance is the patient's responsibility. For a $1,500 injection, that means roughly $300 out of pocket per dose, or $600 per year for two doses.

Medigap (Medicare Supplement) plans can eliminate this coinsurance entirely. Plan F, Plan G, and Plan N all cover Part B coinsurance, bringing the patient's cost to $0 for the Prolia injection itself. Patients enrolled in Medicare Advantage plans should check their specific plan's formulary and prior authorization requirements, as coverage terms vary by insurer and region.

A critical detail: Medicare patients are not eligible for manufacturer copay cards (the FIRST STEP program). Federal anti-kickback statutes prohibit manufacturers from subsidizing cost-sharing for Medicare beneficiaries. However, Medicare patients may qualify for assistance through independent charitable foundations such as the HealthWell Foundation or the Patient Advocate Foundation, which maintain separate denosumab copay funds when available. These funds open and close periodically based on donations, so patients should apply early and check availability quarterly.

Medicaid Coverage by State

All 50 state Medicaid programs cover Prolia, though the specific requirements differ. Some states require prior authorization demonstrating that the patient has tried and failed (or is contraindicated for) an oral bisphosphonate such as alendronate before approving denosumab. Others cover it without step therapy if the prescribing physician documents a clinical rationale.

For Medicaid patients, the out-of-pocket cost for Prolia is typically $0 to $3, depending on the state's nominal copay structure. The Medicaid Drug Rebate Program requires Amgen to provide mandatory rebates to state Medicaid agencies, which keeps the drug on formulary in most states.

Patients dually eligible for Medicare and Medicaid (dual-eligible beneficiaries) receive the most comprehensive coverage. Medicare Part B serves as the primary payer, and Medicaid covers the 20% coinsurance that Medicare does not, effectively reducing the patient's cost to $0.

According to the AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis: "Denosumab is recommended as initial therapy for patients at very high fracture risk, including those with recent fractures, T-scores below −3.0, or high FRAX probability" [5]. This guideline language supports prior authorization requests by documenting medical necessity for patients who need to bypass bisphosphonate step therapy.

Biosimilar Denosumab: A Lower-Cost Alternative

The FDA approved the first biosimilar denosumab products beginning in 2025, and several are now available or nearing launch as of mid-2026. Biosimilars undergo rigorous analytical, preclinical, and clinical testing to confirm they are highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency [6].

Biosimilar pricing for denosumab is expected to run 15% to 35% below the branded Prolia WAC, potentially bringing the per-injection cost to $975 to $1,275 before insurance. For cash-pay patients, GoodRx and similar discount platforms may offer even lower negotiated rates at specific pharmacies and infusion centers.

The AACE has noted that biosimilar adoption in osteoporosis has been slower than in oncology or rheumatology, partly because Prolia is administered only twice per year (making the absolute savings per patient smaller) and partly because of physician and patient hesitancy around switching stable biologic therapy. Patients on Prolia who are considering a switch to a biosimilar should discuss the transition with their prescribing physician, as guidelines generally support switching between a reference biologic and its biosimilar without loss of efficacy or increase in immunogenicity risk [7].

State Pharmaceutical Assistance Programs (SPAPs)

At least 28 states operate their own pharmaceutical assistance programs that can help cover the cost of injectable medications like Prolia for residents who fall into coverage gaps. These programs target patients who earn too much to qualify for Medicaid but too little to afford commercial insurance premiums or high out-of-pocket costs.

Eligibility and benefits vary widely. New York's EPIC program, for example, covers residents aged 65 and older with incomes up to $75,000 (single) or $100,000 (married), charging annual fees of $8 to $300 depending on income. Pennsylvania's PACE program covers residents aged 65 and older with incomes up to $14,500 (single) or $17,700 (married) and charges a $6 copay for brand-name drugs.

Patients can search for their state's program through the National Council on Aging's BenefitsCheckUp tool or by contacting their state's Department of Health. Not all SPAPs cover physician-administered injectables, so patients should specifically ask whether Prolia (HCPCS J0897) is included before enrolling.

How to Build a Long-Term Prolia Access Plan

Because denosumab discontinuation triggers rebound fracture risk, building a durable access strategy matters more for Prolia than for most other osteoporosis medications. The FREEDOM Extension data showed that patients who stopped denosumab after long-term use experienced a rapid rise in bone turnover markers within 3 months, with lumbar spine bone mineral density returning to baseline by 12 to 24 months [2]. Multiple vertebral fractures have been reported within 7 to 18 months of the last dose in patients who discontinued without transitioning to another antiresorptive [3].

A practical access plan should follow these steps:

1. Determine insurance status. Medicare Part B, Medicaid, commercial, or uninsured.
2. Apply for the matching assistance program. Amgen Safety Net (uninsured), FIRST STEP (commercial), independent foundation (Medicare), or SPAP (state-specific).
3. Confirm coverage before the first injection. Do not administer the first dose until funding for at least 2 to 3 years of treatment is secured or a transition plan to an oral bisphosphonate is documented.
4. Set calendar reminders for reapplication. Most assistance programs require annual renewal. Submit paperwork 30 to 60 days before the next dose.
5. Have a discontinuation plan. If cost assistance ends, the prescribing physician should transition the patient to oral alendronate or zoledronic acid (a single IV infusion covered by Part B) to prevent rebound bone loss.

The Endocrine Society recommends that "patients discontinuing denosumab should receive a bisphosphonate, preferably zoledronic acid, to mitigate the rebound increase in bone turnover" [8]. This guidance gives providers a clear fallback if a patient loses financial coverage for Prolia.

Comparing Out-of-Pocket Costs Across Coverage Types

The actual amount a patient pays depends on which combination of insurance and assistance programs applies. Here is a realistic range per injection in 2026:

• Uninsured + Amgen Safety Net Foundation: $0 (if approved)
• Uninsured, no assistance: $1,400 to $1,700 cash price
• Commercial insurance + FIRST STEP copay card: $5 per injection
• Commercial insurance, no copay card: $200 to $600 per injection (depending on coinsurance)
• Medicare Part B + Medigap: $0
• Medicare Part B, no supplement: $250 to $350 per injection
• Medicare Advantage: $0 to $500 per injection (plan-dependent)
• Medicaid: $0 to $3 per injection
• Dual-eligible (Medicare + Medicaid): $0

These figures represent the medication cost only. Provider administration fees (CPT 96372 for subcutaneous injection) may add $20 to $75, though most insurance plans and assistance programs cover this separately.

When to Ask About Zoledronic Acid Instead

For some low-income patients, the most practical solution is not finding a way to afford Prolia but choosing a different medication with a simpler access pathway. Zoledronic acid (Reclast) is a once-yearly IV bisphosphonate that costs $100 to $300 per infusion as a generic. Medicare Part B covers it under the same physician-administered drug benefit as Prolia.

In the HORIZON-PFT trial (N=7,765), zoledronic acid reduced vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years, outcomes comparable to denosumab [9]. Zoledronic acid carries its own considerations (renal function must be adequate, and acute-phase reactions like fever and myalgia occur in 15% to 30% of patients after the first infusion), but its low cost and once-yearly dosing make it a strong alternative for patients who cannot reliably access Prolia long-term.

The choice between denosumab and zoledronic acid should be a shared clinical decision. Patients with an eGFR below 35 mL/min cannot receive zoledronic acid, making denosumab (which has no renal restriction) the preferred agent regardless of cost [5].